Copper-64 based radiopharmaceuticals for brain tumors and hypoxia imaging
- 1 December 2020
- journal article
- review article
- Published by Edizioni Minerva Medica in The Quarterly Journal of Nuclear Medicine and Molecular Imaging
- Vol. 64 (4), 371-381
- https://doi.org/10.23736/s1824-4785.20.03285-9
Abstract
INTRODUCTION: The most common and aggressive primary malignancy of the central nervous system is Glioblastoma that. as a wide range of malignant solid tumor, is characterized by extensive hypoxic regions. A great number of PET radiopharmaceuticals have been developed or the identification of hypoxia in solid tumors, among these, we find copper-based tracers. The aim of the current review paper was to provide an overview of radiocopper compounds applied for preclinical and clinical research in brain tumors and hypoxia imaging or therapy. EVIDENCE ACQUISITION: Copper offers a wide variety of isotopes, useful for nuclear medicine applications, but only Cu-64 and Cu-67 are under the spotlight of the scientific community since being good candidates for theranostic applications. Between the two, Cu-64 availability and production cost have attracted more interest of the scientific community. EVIDENCE SYNTHESIS: In order to better understand the application of copper-bis thiosemicarbazones in hypoxia imaging, an overview of the role of hypoxia in cancer, existing non-imaging and imaging techniques for hypoxia identification and promising future avenues regarding hypoxia is necessary. Different proposed uptake mechanisms of [Cu-64][Cu(ATSM)] inside the cell will be discussed and other Cu-64-based tracers for brain tumors described. CONCLUSIONS: Among radio copper compounds [Cu-64][Cu(AISM)] is the most studied mdiophannaceutical for imaging and treatment of brain tumors. Experimental evidence suggested that [Cu-64][Cu(ATSM)] could be more appropriately considered as a marker of over-reduced intracellular state rather than a pure hypoxia agent. Moreover, preliminary clinical data suggested that [Cu-64]CuCl2 can be a potentially useful diagnostic agent for malignancies of the central nervous system (CNS).Keywords
This publication has 75 references indexed in Scilit:
- NADPH Oxidase Subunit 4-Mediated Reactive Oxygen Species Contribute to Cycling Hypoxia-Promoted Tumor Progression in Glioblastoma MultiformePLOS ONE, 2011
- Positron Emission Tomography Imaging of Cancer Biology: Current Status and Future ProspectsSeminars in Oncology, 2011
- Some thoughts on the mechanism of cellular trapping of Cu(II)-ATSMNuclear Medicine and Biology, 2010
- Pharmacokinetic Analysis of Hypoxia 18F-Fluoromisonidazole Dynamic PET in Head and Neck CancerJournal of Nuclear Medicine, 2009
- Angiogenesis, hypoxia and VEGF expression during tumour growth in a human xenograft tumour modelMicrovascular Research, 2009
- PET Imaging of HypoxiaPET Clinics, 2009
- The impact of O2 availability on human cancerNature Reviews Cancer, 2008
- Examining the relationship between Cu-ATSM hypoxia selectivity and fatty acid synthase expression in human prostate cancer cell linesNuclear Medicine and Biology, 2008
- The 2007 WHO Classification of Tumours of the Central Nervous SystemActa Neuropathologica, 2007
- Efficient production of high specific activity 64Cu using a biomedical cyclotronNuclear Medicine and Biology, 1997